Elvina Almuradova: Olaparib improved ORR and PFS in BRCA-mutated PSR ovarian cancer, but no OS benefit

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on X:

“Final SOLO3 results:

Olaparib improved ORR and PFS vs nonplatinum chemo in BRCA-mut PSR ovarian ca, but no OS benefit (HR 1.07; p=0.71).

Better OS with 2 prior lines (HR 0.83), worse with ≥3 (HR 1.33).

BRCA reversion mutations may explain.”

Elvina Almuradova: Olaparib improved ORR and PFS in BRCA-mutated PSR ovarian cancer, but no OS benefit

More posts featuring Ovarian cancer.